Can you take Enzalutamide with Estrone?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- enzalutamide
- estrone
Drug interactions
Moderate drug interactions
Moderate:
estrone enzalutamide
Applies to: estrone and enzalutamide
Enzalutamide may reduce the blood levels and effects of estrone.
If you are using low-dose oral contraceptives, you may have an increased risk of breakthrough bleeding and unintended pregnancy. You should discuss the use of alternative or additional methods of birth control with your healthcare provider.
If you take hormone replacement for menopause, notify your doctor if your medication is no longer controlling your symptoms or you experience abnormal bleeding.
You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Minor food/lifestyle interactions
Minor:
estrone Food/Lifestyle
Applies to: estrone
Information for this minor interaction is available on the professional version.
Disease interactions
6 potential interactions Applies to: 6 conditions, including Seizures, Head Injury, Brain Tumor, Renal Dysfunction, and History - Cerebrovascular Disease.
Brain Tumor
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Brain Tumor.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
CNS Infection
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with CNS Infection.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Head Injury
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Head Injury.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
History - Cerebrovascular Disease
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with History - Cerebrovascular Disease.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Renal Dysfunction
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Renal Dysfunction.
Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.
Seizures
Moderate:
enzalutamide
Enzalutamide has a moderate potential interaction with Seizures.
Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
Report options
More resources
enzalutamide
A total of 703 drugs are known to interact with enzalutamide.
- Enzalutamide is in the following drug classes: antiandrogens, hormones/antineoplastics.
- Enzalutamide is used to treat Prostate Cancer.
estrone
A total of 273 drugs are known to interact with estrone.
- Estrone is in the drug class estrogens.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.